← Back to all trials
Active Not Recruiting
NCT07726329
Dendritic Cell-immunotherapy for Advanced Hepatocellular Carcinoma
Conditions: Liver Neoplasms
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE2
Enrollment: 100
Sponsor: Chang Gung Memorial Hospital
Location: Chang-Gung Memorial Hospital Taoyuan
Summary
The prognosis of advanced hepatocellular carcinoma is poor. In this study, the eligible patients will be treated by tumor antigen-pulsed autologous dendritic cells and followed by TACE. The end points are to see tumor response and patient survival.
Eligibility Criteria
Inclusion Criteria:
* advanced HCC patients, no response to standard treatment; WBC : 3000-12000/ul; platelet: \>80000/ul; anticipated survival \> 3 months, measurable tumors.
Exclusion Criteria:
* HIV; BCLC stage; acute infection; sepsis; other advanced malignancy; acute liver failure;
Source: ClinicalTrials.gov (NCT07726329). StuddyBuddy aggregates publicly available trial information.
